AI Designs a Custom Virus to Fight a Deadly Drug-Resistant Infection in a Human Patient

A World First in the Fight Against Superbugs

For the first time in history, a virus designed by artificial intelligence has been administered to a human patient to treat a life-threatening bacterial infection. In what is being called the world's first clinical use of AI-generated phages, Omnii-1 designs were administered to a human patient under compassionate use — a regulatory pathway that allows experimental treatments when no other options remain. The announcement, made on October 20, 2026, by US-based biotech startup Radical Numerics, marks a stunning convergence of artificial intelligence and biology at a moment when the world desperately needs new tools to fight infection.

Drug-resistant infections were linked to an estimated 4.95 million deaths worldwide in 2019, and for patients whose infections no longer respond to antibiotics, few options remain. Antibiotic resistance is a growing global concern, projected to cause approximately 40 million deaths over the next 25 years. The stakes couldn't be higher — and that's exactly why what Radical Numerics is attempting matters so much.

How AI Built a Better Virus

One alternative to antibiotics is bacteriophages — viruses that kill bacteria. But finding a phage that works against a particular patient's infection can take months and often fails. Radical Numerics took a radically different approach. Instead of searching for the right virus, they designed one. Their AI model, called Omnii-1, was trained on vast amounts of genomic data and tasked with engineering a solution from scratch.

In this specific case, the patient was battling a strain of E. coli that had become a nightmare to treat. The bacteria had resisted not just antibiotics but all available phages. The researchers trained Omnii with information about the resistant strain and told it to design T7 phages with legs that could grab onto the bacteria. The AI generated 700,000 virus genomes. The team synthesized DNA molecules from 285 genomes and inserted them into bacteria, and found that 16 of the genomes gave rise to viable viruses. Researchers used Omnii to design phages targeting the patient's persistent drug-resistant infection within weeks. A cocktail containing an AI-designed phage killed the patient's bacterial isolate in laboratory testing and was then administered at a clinical site under a physician compassionate use access.

Promising — But Not Without Skeptics

The report has not been peer reviewed or published in a scientific journal, though company officials said the trial had been authorized by the Food and Drug Administration. That distinction matters. Some scientists are skeptical that lab success will translate to results inside a human body, and others have raised broader concerns about the practice of engineering viruses as a field. Results from the patient's treatment could still be months away.

Phages do not infect human cells, and phage therapy is generally considered safe. Unlike broad-spectrum antibiotics, phages can target particular bacteria with remarkable specificity, sparing beneficial bacteria such as those in the gut that support digestion. Still, the science is early. Only a few clinical requests for phage therapy have been fulfilled successfully, due to a lack of understanding of the biology of phage-host interactions and resistance development, the human immune response to phage particles, and the right phage dosage and pharmacokinetics.

The Bigger Picture for Medicine

The urgency behind this work is hard to overstate. Resistance to antibiotics is not a future problem — it is already here. The World Health Organization tracked antibiotic resistance increasing in more than 40% of the bacteria-antibiotic combinations it monitored between 2018 and 2023. Radical Numerics is also demonstrating Omnii across eight applications, including personalized cancer vaccine design, identifying the genetic causes of rare diseases, and detecting emerging biological threats. The phage therapy case is just one chapter in a much larger story about what AI-designed biology could do.

If this treatment works, it could fundamentally change how medicine approaches infection — not by searching for an existing solution, but by building a custom one in days. For patients with severe infections and few remaining options, delays in finding effective treatment can be life-threatening. AI-designed phage therapy won't replace antibiotics overnight, but it may represent the beginning of a new era — one where the answer to a deadly infection is no longer found in nature, but written by a machine.